Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2019-06-13 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Update on Etigilimab (TIGIT) Partnership
Regulatory Filings Classification · 98% confidence The document is an official announcement from Mereo BioPharma Group plc regarding a change in a partnership agreement with Celgene Corporation. It is distributed via the Regulatory News Service (RNS) of the London Stock Exchange. While it discusses a business development, it does not fit into specific categories like M&A (which usually refers to the acquisition of the company itself or a major business unit) or Earnings Releases. As it is a general regulatory announcement regarding corporate strategy and partnership status, it falls under the RNS (Regulatory Filings) category.
2019-06-13 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, pursuant to SEC rules. It contains detailed clinical trial data updates, including interim results from a phase 2b study, and announces an upcoming conference call for analysts and investors. The document is not a full annual or quarterly report but rather a periodic update on clinical progress and business developments. It is not an earnings release since it focuses on clinical data rather than financial results. The presence of a conference call announcement and detailed discussion of study data aligns with a Call Transcript or Investor Presentation, but the document is a formal SEC filing (Form 6-K) and not a transcript. The content is primarily an operational and clinical update with some business outlook, typical of a Capital/Financing Update or Regulatory Filing. However, since it is a formal SEC filing reporting clinical trial progress and upcoming data release, and includes a conference call announcement, the best fit is Capital/Financing Update (CAP) as it relates to company progress and investor communication about clinical milestones and expected data releases. The document length (over 14,000 characters) and detailed content confirm it is not a brief announcement or a report publication announcement. Therefore, the classification is CAP with high confidence.
2019-05-30 English
Positive early 6 month data
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) by Mereo BioPharma Group plc. It details interim clinical trial results (Phase 2b study for setrusumab). While it contains financial-adjacent information regarding clinical progress, it is an initial announcement of results rather than a full financial report or a transcript. According to the provided definitions, this fits the 'Earnings Release' (ER) category as it is an initial announcement of key highlights/results, or alternatively 'Regulatory Filings' (RNS). Given the specific nature of the clinical data announcement, 'ER' is the most appropriate classification for a corporate results release.
2019-05-30 English
20-F/A
Annual Report FY 2018
2019-05-29 English
FORM 6-K
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed by Mereo BioPharma Group plc, which is a report of a foreign private issuer pursuant to SEC rules. The content details notifications of share purchases by directors and persons discharging managerial responsibilities (PDMRs), including specific transaction details such as dates, prices, and volumes. This matches the description of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document is not an annual or quarterly report, nor an earnings release or other financial report. It is not a regulatory filing or announcement of a report but a direct notification of insider transactions. Therefore, the correct classification is Director's Dealing (DIRS).
2019-05-23 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is titled 'Notification of PDMR and Director Dealing' and explicitly details share purchases by a Director (Peter Bains) and a member of senior management (John Richard). It follows the standard EU Market Abuse Regulation disclosure format for transactions by persons discharging managerial responsibilities (PDMRs). This aligns perfectly with the definition for 'Director's Dealing'.
2019-05-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.